Revolutionizing Inflammation Treatment: Novartis’ $835M Deal Sparks Excitement in Biopharma World

Novartis acquires IFM Due, a developer of STING antagonists for inflammatory diseases, for $90M upfront and up to $745M in milestone payments, with an option agreement initiated in 2019.










